Yaso Therapeutics Receives $2 Million Award from NICHD
Yaso Therapeutics, Inc. announces the award of a fourth SBIR grant from the National Institutes of Health (NIH), enabling the firm to complete preclinical testing of a novel polymer, PPCM, as a contraceptive. The drug also shows promise in preventing sexually transmitted infections (STIs).
Modified on August 10, 2017